NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis $2.05 +0.02 (+0.99%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cellectar Biosciences Stock (NASDAQ:CLRB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cellectar Biosciences alerts:Sign Up Key Stats Today's Range$2.03▼$2.1350-Day Range$1.91▼$2.2052-Week Range$1.82▼$4.45Volume160,123 shsAverage Volume925,636 shsMarket Capitalization$73.49 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company OverviewCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More… Protect Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Cellectar Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks55th Percentile Overall ScoreCLRB MarketRank™: Cellectar Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 624th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectar Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Cellectar Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.57) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cellectar Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.65% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 10.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.65% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 10.91%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment0.96 News SentimentCellectar Biosciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cellectar Biosciences this week, compared to 1 article on an average week.Search Interest3 people have searched for CLRB on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions.Read more about Cellectar Biosciences' insider trading history. Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CLRB Stock News HeadlinesCellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News SummaryOctober 20, 2024 | benzinga.comIopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaAugust 26, 2024 | stockhouse.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 29, 2024 | Porter & Company (Ad)Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaAugust 26, 2024 | globenewswire.comCellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from NasdaqAugust 23, 2024 | globenewswire.comCLRB Sep 2024 5.000 callAugust 18, 2024 | ca.finance.yahoo.comCLRB Sep 2024 2.500 callAugust 17, 2024 | ca.finance.yahoo.comOppenheimer Keeps Their Buy Rating on Cellectar Biosciences (CLRB)August 15, 2024 | markets.businessinsider.comSee More Headlines CLRB Stock Analysis - Frequently Asked Questions How have CLRB shares performed this year? Cellectar Biosciences' stock was trading at $2.77 at the beginning of 2024. Since then, CLRB stock has decreased by 26.0% and is now trading at $2.05. View the best growth stocks for 2024 here. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.10. When did Cellectar Biosciences' stock split? Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Cellectar Biosciences' major shareholders? Top institutional shareholders of Cellectar Biosciences include Sequoia Financial Advisors LLC (0.07%). View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Hudbay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings11/07/2021Today10/29/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLRB CUSIPN/A CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$28.00 Low Stock Price Target$14.00 Potential Upside/Downside+924.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,980,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-200.45% Debt Debt-to-Equity RatioN/A Current Ratio2.54 Quick Ratio2.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-5.69Miscellaneous Outstanding Shares35,850,000Free Float34,523,000Market Cap$73.49 million OptionableOptionable Beta0.99 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CLRB) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.